134 related articles for article (PubMed ID: 34844036)
1. Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells.
Piven YA; Yastrebova MA; Khamidullina AI; Scherbakov AM; Tatarskiy VV; Rusanova JA; Baranovsky AV; Zinovich VG; Khlebnicova TS; Lakhvich FA
Bioorg Med Chem; 2022 Jan; 53():116521. PubMed ID: 34844036
[TBL] [Abstract][Full Text] [Related]
2. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
6. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
Nguyen CT; Ann J; Sahu R; Byun WS; Lee S; Nam G; Park HJ; Park S; Kim YJ; Kim JY; Seo JH; Lee J
Bioorg Med Chem Lett; 2020 Sep; 30(17):127374. PubMed ID: 32738983
[TBL] [Abstract][Full Text] [Related]
8. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors.
Lee JH; Shin SC; Seo SH; Seo YH; Jeong N; Kim CW; Kim EE; Keum G
Bioorg Med Chem Lett; 2017 Jan; 27(2):237-241. PubMed ID: 27914802
[TBL] [Abstract][Full Text] [Related]
11. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.
Jiang F; Guo AP; Xu JC; Wang HJ; Mo XF; You QD; Xu XL
Eur J Med Chem; 2017 Dec; 141():1-14. PubMed ID: 29028527
[TBL] [Abstract][Full Text] [Related]
12. Identification of New Hsp90 Inhibitors: Structure Based Virtual Screening, Molecular Dynamic Simulation, Synthesis and Biological Evaluation.
Abbasi M; Amanlou M; Aghaei M; Hassanzadeh F; Sadeghi-Aliabadi H
Anticancer Agents Med Chem; 2021; 21(18):2583-2591. PubMed ID: 33563187
[TBL] [Abstract][Full Text] [Related]
13. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
14. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors.
Kadasi S; Costa TEMM; Arukala N; Toshakani M; Duggineti C; Thota S; Dutta Gupta S; Raj S; Penido C; Henriques MG; Raghavendra NM
Med Chem; 2018; 14(1):44-52. PubMed ID: 28641528
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel celastrol-triazole derivatives with Hsp90-Cdc37 disruption to induce tumor cell apoptosis.
Li N; Chen C; Zhu H; Shi Z; Sun J; Chen L
Bioorg Chem; 2021 Jun; 111():104867. PubMed ID: 33845380
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of Synthesized 1,4-Naphthoquinone Oxime Derivatives on Selected Human Cancer Cell Lines.
Zhang Q; Dong J; Cui J; Huang G; Meng Q; Li S
Chem Pharm Bull (Tokyo); 2018; 66(6):612-619. PubMed ID: 29863062
[TBL] [Abstract][Full Text] [Related]
18. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
[TBL] [Abstract][Full Text] [Related]
19. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
